Long-Term Risk of Cervical Precancer after HPV, Cytology Screening

As cervical cancer screening shifts from cytology or cotesting (cytology plus human papillomavirus [HPV] testing) to primary HPV testing, questions remain about patients’ longer-term risk of precancer. To learn more, investigators studied 8100 Canadian women who, as part of a prior trial, underwent cotesting at trial exit (median age, 49). After the trial ended, patients reverted to routine cytology-based screening per local guidelines, and the investigators assessed 10-year risk of cervical intraepithelial neoplasia grade 2 or higher (CIN2+) according to cotesting results.